Clinical validation of the First Implantable Sensor System for Wireless detectio...
Clinical validation of the First Implantable Sensor System for Wireless detection of stent occlusion/ restenosis
Globally, over 237 million people suffer from peripheral artery disease (PAD), an abnormal narrowing of the arteries. The implantation of stents (spiral wire protheses) is the first-line therapy for PAD with ~ 3.5M stents implante...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
2ND-CHANCE
Implantable sensors and ultrasonic data link with triggered...
3M€
Cerrado
NIMBLE WOMENTECHEU
A novel non-invasive and non-ionizing medical device for mon...
75K€
Cerrado
NIMBLE System
"The NIMBLE System: A novel non-invasive and non-ionizing me...
3M€
Cerrado
RTI2018-093512-B-C21
MONITORIZACION EN TIEMPO REAL DE VARIABLES HEMODINAMICAS CON...
100K€
Cerrado
TEC2013-46242-C3-3-P
SISTEMA-EN-CHIP MULTI-CANAL DE PREDICCION Y MONITORIZACION D...
106K€
Cerrado
RTC-2016-5439-1
EneHeart (Sistema de medición de gasto cardiaco no invasivo)
330K€
Cerrado
Información proyecto StentGuard
Duración del proyecto: 47 meses
Fecha Inicio: 2022-10-21
Fecha Fin: 2026-09-30
Líder del proyecto
VESSELSENS GMBH
No se ha especificado una descripción o un objeto social para esta compañía.
Presupuesto del proyecto
11M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Globally, over 237 million people suffer from peripheral artery disease (PAD), an abnormal narrowing of the arteries. The implantation of stents (spiral wire protheses) is the first-line therapy for PAD with ~ 3.5M stents implanted worldwide every year. Restenosis, the gradual reclogging
of the blood vessel after stent implantation, is a major problem leading to high morbidity and mortality which occurs within 6 years after implantation in ~23 % of all cases and is often detected when it is too late. More frequent surveillance of PAD patients to avoid unnecessary amputations
and death is an unmet clinical challenge. VesselSens is developing the StentGuard, a smart therapeutic monitoring device that enables rapid, low cost, early diagnosis of restenosis non-invasively and reliably. This device allows stent monitoring at high frequencies with low cost by
non-specialist medical practitioners solving the problem of unchecked disease progression and saving the EU economy over €1bn/ year.